Topgen takes high-throughput sequencing as its core technology to provide early and precision-oriented detection of cancer and cellular immunotherapy services.
Topgen (Chinese: 鼎晶生物) completed the Series D1 round of financing worth over CNY 100 million. This funding round was jointly invested by CAS Holdings (Chinese: 国科联动), Chuangda Funeng (Chinese: 创达富能), Sanya Yazhouwan Venture Capital (Chinese: 三亚崖州湾创业投资有限公司) and Changshi (Sanya) Venture Capital (Chinese:长石（三亚）创业投资).
The company just scored a CNY 120 million (USD 20 million) funding round in 2021. After this round of financing, the company intends to accelerate the construction of the precision medical system and initial public offering process.
Founded in 2012, Topgen is a high-tech enterprise dedicated to the research, development, and sale of technologies and products in precision medicine.
With high-throughput sequencing as the core technology, the company has built laboratory-developed test and in vitro diagnosis systems through self-developed reagents. Topgen provides services in early cancer screening, concomitant medication, prognosis monitoring, and precise medication guidance for chronic diseases and infectious diseases.
In addition to Topgen, the domestic listed enterprises in precision medicine also include BGI (Chinese:华大基因, 300676), Berry Genomics (Chinese: 贝瑞基因, 000710), Daan Gene (Chinese: 达安基因, 002030) and AmoyDx (Chinese: 艾德生物,300685).